{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:14:43Z","timestamp":1784128483508,"version":"3.55.0"},"reference-count":114,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Italian Ministry of Health"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>In-transit metastases (ITM) in melanoma present a significant therapeutic challenge due to their advanced stage and complex clinical nature. From traditional management with surgical resection, ITM treatment has evolved with the advent of systemic therapies such as immune checkpoint inhibitors and targeted therapies, which have markedly improved survival outcomes. This study aims to review and highlight the efficacy of both systemic and locoregional treatment approaches for ITM. Methods include a comprehensive review of clinical studies examining the impact of treatments like immune checkpoint inhibitors, targeted therapies, Isolated Limb Perfusion, and electrochemotherapy. The results indicate that combining systemic therapies with locoregional treatments enhances both local disease control and overall survival rates. The introduction of modern immunotherapies has not diminished the effectiveness of locoregional therapies but rather improved patient outcomes when used in conjunction. The conclusions emphasize that a multidisciplinary approach integrating systemic and locoregional therapies offers a promising strategy for optimizing the management of ITM in melanoma patients. This integrated treatment model not only improves survival rates but also enhances the quality of life for patients, suggesting a shift in standard care practices toward more comprehensive therapeutic regimens.<\/jats:p>","DOI":"10.3390\/cancers16173065","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T04:06:41Z","timestamp":1725336401000},"page":"3065","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Therapeutic Treatment Options for In-Transit Metastases from Melanoma"],"prefix":"10.3390","volume":"16","author":[{"given":"Francesco","family":"Russano","sequence":"first","affiliation":[{"name":"Soft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Rastrelli","sequence":"additional","affiliation":[{"name":"Soft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, 35128 Padova, Italy"},{"name":"Department of Surgical, Oncological and Gastroenterological Sciences (DISCOG), University of Padua, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1564-2594","authenticated-orcid":false,"given":"Luigi","family":"Dall\u2019Olmo","sequence":"additional","affiliation":[{"name":"Soft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, 35128 Padova, Italy"},{"name":"Department of Surgical, Oncological and Gastroenterological Sciences (DISCOG), University of Padua, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2862-8014","authenticated-orcid":false,"given":"Paolo","family":"Del Fiore","sequence":"additional","affiliation":[{"name":"Soft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlomaria","family":"Gianesini","sequence":"additional","affiliation":[{"name":"Department of Surgical, Oncological and Gastroenterological Sciences (DISCOG), University of Padua, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Vecchiato","sequence":"additional","affiliation":[{"name":"Soft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4575-0548","authenticated-orcid":false,"given":"Marcodomenico","family":"Mazza","sequence":"additional","affiliation":[{"name":"Soft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saveria","family":"Tropea","sequence":"additional","affiliation":[{"name":"Soft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9433-8445","authenticated-orcid":false,"given":"Simone","family":"Mocellin","sequence":"additional","affiliation":[{"name":"Soft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, 35128 Padova, Italy"},{"name":"Department of Surgical, Oncological and Gastroenterological Sciences (DISCOG), University of Padua, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3322\/caac.21409","article-title":"Melanoma Staging: Evidence-based Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1080\/14737140.2018.1489246","article-title":"The Eighth Edition American Joint Committee on Cancer (AJCC) Melanoma Staging System: Implications for Melanoma Treatment and Care","volume":"18","author":"Keung","year":"2018","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/bjs.11149","article-title":"Meta-Analysis of Completion Lymph Node Dissection in Sentinel Lymph Node-Positive Melanoma","volume":"106","author":"Angeles","year":"2019","journal-title":"Br. J. Surg."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1056\/NEJMoa060992","article-title":"Sentinel-Node Biopsy or Nodal Observation in Melanoma","volume":"355","author":"Morton","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1245\/s10434-014-4100-0","article-title":"In-Transit Melanoma Metastases: Incidence, Prognosis, and the Role of Lymphadenectomy","volume":"22","author":"Read","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/ans.14921","article-title":"Management of In-transit Melanoma Metastases: A Review","volume":"89","author":"Henderson","year":"2019","journal-title":"ANZ J. Surg."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Tian, J., and Quek, C. (2024). Understanding the Tumor Microenvironment in Melanoma Patients with In-Transit Metastases and Its Impacts on Immune Checkpoint Immunotherapy Responses. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25084243"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s10585-021-10100-3","article-title":"In-Transit Metastatic Cutaneous Melanoma: Current Management and Future Directions","volume":"39","author":"Patel","year":"2022","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/S0002-9440(10)64088-6","article-title":"Molecular Clonality of In-Transit Melanoma Metastasis","volume":"158","author":"Nakayama","year":"2001","journal-title":"Am. J. Pathol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.gendis.2022.04.004","article-title":"Melanoma: Molecular Genetics, Metastasis, Targeted Therapies, Immunotherapies, and Therapeutic Resistance","volume":"9","author":"Wagstaff","year":"2022","journal-title":"Genes Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"7019","DOI":"10.1245\/s10434-022-11997-0","article-title":"Clinicopathological Characteristics Predicting Further Recurrence and Survival Following Resection of In-Transit Melanoma Metastases","volume":"29","author":"Lawless","year":"2022","journal-title":"Ann. Surg. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S694","DOI":"10.1016\/j.annonc.2023.09.2982","article-title":"1166P Multi-Modal and Longitudinal Characterization of the Tumor and Immune Microenvironment from Primary Melanoma to in-Transit and Distant Metastasis","volume":"34","author":"Tarantino","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"9586","DOI":"10.1200\/JCO.2024.42.16_suppl.9586","article-title":"Characterization of Driver Oncogenic Mutations of In-Transit Melanoma Metastases","volume":"42","author":"Kim","year":"2024","journal-title":"JCO"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/ajcp\/aqv015","article-title":"Immunohistochemical Detection of NRAS Q61R Mutation in Diverse Tumor Types","volume":"145","author":"Su","year":"2016","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.phrs.2016.03.007","article-title":"Targeting Mutant NRAS Signaling Pathways in Melanoma","volume":"107","author":"Vu","year":"2016","journal-title":"Pharmacol. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"102238","DOI":"10.1016\/j.ctrv.2021.102238","article-title":"NRAS Mutant Melanoma: Towards Better Therapies","volume":"99","author":"Randic","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/CMR.0000000000000808","article-title":"Tumor Mutational Burden and Somatic Mutation Status to Predict Disease Recurrence in Advanced Melanoma","volume":"32","author":"Hotz","year":"2022","journal-title":"Melanoma Res."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Neittaanm\u00e4ki, N., Zaar, O., Cehajic, K.S., Nilsson, K.D., Katsarelias, D., Bagge, R.O., Paoli, J., and Fletcher, J.S. (2024). ToF-SIMS Imaging Reveals Changes in Tumor Cell Lipids during Metastatic Progression of Melanoma. Pigment. Cell Melanoma Res., Epub ahead of print.","DOI":"10.1111\/pcmr.13182"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/ijd.16141","article-title":"Association of Tumor Molecular Factors with In-transit Metastasis in Primary Cutaneous Melanoma","volume":"61","author":"Jakub","year":"2022","journal-title":"Int. J. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41590-022-01141-1","article-title":"A Decade of Checkpoint Blockade Immunotherapy in Melanoma: Understanding the Molecular Basis for Immune Sensitivity and Resistance","volume":"23","author":"Huang","year":"2022","journal-title":"Nat. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of Antitumor Immunity by CTLA-4 Blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved Survival with Ipilimumab in Patients with Metastatic Melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00262-016-1856-z","article-title":"Immune Checkpoint Blockade with Concurrent Electrochemotherapy in Advanced Melanoma: A Retrospective Multicenter Analysis","volume":"65","author":"Heppt","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s11912-022-01216-0","article-title":"Management of In-Transit Metastases","volume":"24","author":"Queiroz","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.phrs.2011.09.002","article-title":"Ipilimumab: A Novel Immunostimulatory Monoclonal Antibody for the Treatment of Cancer","volume":"65","author":"Graziani","year":"2012","journal-title":"Pharmacol. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1056\/NEJMra2034861","article-title":"Recent Advances in the Treatment of Melanoma","volume":"384","author":"Curti","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2022.03.041","article-title":"The Efficacy of Immune Checkpoint Blockade for Melanoma In-Transit with or without Nodal Metastases\u2014A Multicenter Cohort Study","volume":"169","author":"Holmberg","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e000440","DOI":"10.1136\/jitc-2019-000440","article-title":"Efficacy of Immune Checkpoint Inhibitors for In-Transit Melanoma","volume":"8","author":"Rtshiladze","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse Effects of Immune-Checkpoint Inhibitors: Epidemiology, Management and Surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Sheng, J., Nayeni, M., and Malvankar, M. (2024). The Relationship between Immune-Related Adverse Events during Ipilimumab Monotherapy and Survival Outcomes among Melanoma Patients: A Systematic Review. J. Oncol. Pharm. Pr., Epub ahead of print.","DOI":"10.1177\/10781552241243042"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The Future of Immune Checkpoint Therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Dong, H., and Markovic, S.N. (2024). The Basics of Cancer Immunotherapy, Springer International Publishing.","DOI":"10.1007\/978-3-031-59475-5"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in Previously Untreated Melanoma without BRAF Mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma (KEYNOTE-006): Post-Hoc 5-Year Results from an Open-Label, Multicentre, Randomised, Controlled, Phase 3 Study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-Checkpoint Inhibitors: Long-Term Implications of Toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1200\/JCO.18.01998","article-title":"Evaluation of Two Dosing Regimens for Nivolumab in Combination with Ipilimumab in Patients with Advanced Melanoma: Results from the Phase IIIb\/IV CheckMate 511 Trial","volume":"37","author":"Meyer","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus Ipilimumab or Nivolumab Alone versus Ipilimumab Alone in Advanced Melanoma (CheckMate 067): 4-Year Outcomes of a Multicentre, Randomised, Phase 3 Trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"9516","DOI":"10.1200\/JCO.2021.39.15_suppl.9516","article-title":"Two Dosing Regimens of Nivolumab (NIVO) plus Ipilimumab (IPI) for Advanced (Adv) Melanoma: Three-Year Results of CheckMate 511","volume":"39","author":"Lebbe","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/bjd.18739","article-title":"Neoadjuvant Immunotherapy with Combined Ipilimumab and Nivolumab in Patients with Melanoma with Primary or in Transit Disease","volume":"183","author":"Weber","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4994","DOI":"10.1158\/1078-0432.CCR-14-0776","article-title":"FDA Approval Summary: Vemurafenib for Treatment of Unresectable or Metastatic Melanoma with the BRAFV600E Mutation","volume":"20","author":"Kim","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1177\/1060028013513009","article-title":"Dabrafenib Therapy for Advanced Melanoma","volume":"48","author":"Trinh","year":"2014","journal-title":"Ann. Pharmacother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature09626","article-title":"Melanomas Acquire Resistance to B-RAF(V600E) Inhibition by RTK or N-RAS Upregulation","volume":"468","author":"Nazarian","year":"2010","journal-title":"Nature"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/1758834014566428","article-title":"Management of BRAF and MEK Inhibitor Toxicities in Patients with Metastatic Melanoma","volume":"7","author":"Welsh","year":"2015","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nrc4000","article-title":"MEK1 and MEK2 Inhibitors and Cancer Therapy: The Long and Winding Road","volume":"15","author":"Caunt","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib","volume":"372","author":"Caroline","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s11912-023-01385-6","article-title":"Chemotherapy in Cutaneous Melanoma: Is There Still a Role?","volume":"25","author":"Pham","year":"2023","journal-title":"Curr. Oncol. Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1089\/bioe.2023.0041","article-title":"The Efficacy of Electrochemotherapy with Dacarbazine on Melanoma Cells","volume":"6","author":"Coskun","year":"2024","journal-title":"Bioelectricity"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1038\/s41416-021-01486-8","article-title":"Impact of Prior Treatment with Immune Checkpoint Inhibitors on Dacarbazine Efficacy in Metastatic Melanoma","volume":"125","author":"Bouchereau","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2217\/mmt-2017-0003","article-title":"The Role for Chemotherapy in the Modern Management of Melanoma","volume":"4","author":"Gupta","year":"2017","journal-title":"Melanoma Manag."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"10646","DOI":"10.1021\/bi970791q","article-title":"Mechanism of Action of Fotemustine, a New Chloroethylnitrosourea Anticancer Agent:\u2009 Evidence for the Formation of Two DNA-Reactive Intermediates Contributing to Cytotoxicity","volume":"36","author":"Hayes","year":"1997","journal-title":"Biochemistry"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1200\/JCO.2004.04.165","article-title":"Fotemustine Compared with Dacarbazine in Patients with Disseminated Malignant Melanoma: A Phase III Study","volume":"22","author":"Avril","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1002\/1097-0142(19901101)66:9<1873::AID-CNCR2820660904>3.0.CO;2-5","article-title":"Final Report of the French Multicenter Phase II Study of the Nitrosourea Fotemustine in 153 Evaluable Patients with Disseminated Malignant Melanoma Including Patients with Cerebral Metastases","volume":"66","author":"Jacquillat","year":"1990","journal-title":"Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1634\/theoncologist.12-9-1114","article-title":"Temozolomide for the Treatment of Metastatic Melanoma: A Systematic Review","volume":"12","author":"Quirt","year":"2007","journal-title":"Oncologist"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00008390-200204000-00011","article-title":"Effect of Temozolomide on Central Nervous System Relapse in Patients with Advanced Melanoma","volume":"12","author":"Paul","year":"2002","journal-title":"Melanoma Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.clindermatol.2012.08.016","article-title":"Chemotherapy in the Management of Advanced Cutaneous Malignant Melanoma","volume":"31","author":"Luke","year":"2013","journal-title":"Clin. Dermatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1245\/s10434-010-1104-2","article-title":"Long-Term Results of Melphalan-Based Isolated Limb Perfusion With or Without Low-Dose TNF for In-Transit Melanoma Metastases","volume":"17","author":"Rossi","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"108050","DOI":"10.1016\/j.ejso.2024.108050","article-title":"Technical Considerations for Isolated Limb Perfusion: A Consensus Paper","volume":"50","author":"Hayes","year":"2024","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1634\/theoncologist.2009-0325","article-title":"Isolated Limb Perfusion for Malignant Melanoma: Systematic Review on Effectiveness and Safety","volume":"15","author":"Ferrandiz","year":"2010","journal-title":"Oncologist"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/01.sla.0000251746.02764.fc","article-title":"Long-Term Results of Hyperthermic, Isolated Limb Perfusion for Melanoma: A Reflection of Tumor Biology","volume":"245","author":"Sanki","year":"2007","journal-title":"Ann. Surg."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jss.2017.03.066","article-title":"Melphalan Hypoxic Perfusion with Hemofiltration for Melanoma Locoregional Metastases in the Pelvis","volume":"215","author":"Guadagni","year":"2017","journal-title":"J. Surg. Res."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Guadagni, S., Fiorentini, G., Clementi, M., Palumbo, G., Palumbo, P., Chiominto, A., Baldoni, S., Masedu, F., Valenti, M., and Tommaso, A.D. (2017). Does Locoregional Chemotherapy Still Matter in the Treatment of Advanced Pelvic Melanoma?. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18112382"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jss.2021.05.054","article-title":"A Prospective Study of Intraarterial Infusion Chemotherapy in Advanced Wild-Type BRAF Melanoma Patients","volume":"268","author":"Guadagni","year":"2021","journal-title":"J. Surg. Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.ejso.2016.10.005","article-title":"Diagnosis and Treatment of In-Transit Melanoma Metastases","volume":"43","author":"Testori","year":"2017","journal-title":"Eur. J. Surg. Oncol. (EJSO)"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Dugan, M.M., Shannon, A.B., DePalo, D.K., Perez, M.C., and Zager, J.S. (2024). Intralesional and Infusional Updates for Metastatic Melanoma. Cancers, 16.","DOI":"10.3390\/cancers16111957"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Sevilla-Ortega, L., Ferr\u00e1ndiz-Pulido, L., Palaz\u00f3n-Carri\u00f3n, N., \u00c1lamo De La Gala, M.D.C., De Toro-Salas, R., Garnacho-Montero, J., Marcos-Rodr\u00edguez, J.A., Agudo Mart\u00ednez, A., Araji-Tiliani, O., and Calvo-Mor\u00f3n, M.C. (2021). Role of Isolated Limb Perfusion in the Era of Targeted Therapies and Immunotherapy in Melanoma. A Systematic Review of The Literature. Cancers, 13.","DOI":"10.3390\/cancers13215485"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1245\/s10434-019-07288-w","article-title":"Long\u2013Term Oncologic Outcomes After Isolated Limb Infusion for Locoregionally Metastatic Melanoma: An International Multicenter Analysis","volume":"26","author":"Miura","year":"2019","journal-title":"Ann. Surg. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1080\/0284186X.2018.1454602","article-title":"Updated Standard Operating Procedures for Electrochemotherapy of Cutaneous Tumours and Skin Metastases","volume":"57","author":"Gehl","year":"2018","journal-title":"Acta Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Zdzienicki, M., Zi\u0119tek, M., Krotewicz, M., Ewert-Krzemieniewska, A., and Rutkowski, P. (2024). The Long-Term Results of Electrochemotherapy in the Treatment of Patients with Locoregionally Advanced, Unresectable Melanoma. J. Clin. Med., 13.","DOI":"10.3390\/jcm13133705"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1080\/0284186X.2021.2006776","article-title":"Impact of Electrochemotherapy in Metastatic Cutaneous Melanoma: A Contemporary Systematic Review and Meta-Analysis","volume":"61","author":"Petrelli","year":"2022","journal-title":"Acta Oncol."},{"key":"ref_76","first-page":"17","article-title":"Treatment for Melanoma of the Lower Extremity with Intralesional Injection of Bacille Calmette Gu\u00e9rin and Hyperthermic Perfusion","volume":"149","author":"Storm","year":"1979","journal-title":"Surg. Gynecol. Obstet."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/j.1524-4725.1993.tb00989.x","article-title":"Pooled Analysis of the Efficacy of Bacille Calmette-Guerin (BCG) Immunotherapy in Malignant Melanoma","volume":"19","author":"Tan","year":"1993","journal-title":"Dermatol. Surg."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1001\/archsurg.1976.01360240096018","article-title":"BCG Immunotherapy in Patients with Malignant Melanoma","volume":"111","author":"Karakousis","year":"1976","journal-title":"Arch. Surg."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Cardillo, F., Bonfim, M., Da Silva Vasconcelos Sousa, P., Mengel, J., Ribeiro Castello-Branco, L.R., and Pinho, R.T. (2021). Bacillus Calmette\u2013Gu\u00e9rin Immunotherapy for Cancer. Vaccines, 9.","DOI":"10.3390\/vaccines9050439"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/jso.23702","article-title":"Treatment of In-transit Melanoma with Intra-lesional Interleukin-2: A Systematic Review","volume":"110","author":"Byers","year":"2014","journal-title":"J. Surg. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/jso.26121","article-title":"Lesional Therapies for In-transit Melanoma","volume":"122","author":"Nadler","year":"2020","journal-title":"J. Surg. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/jso.23556","article-title":"Intra-Lesional Interleukin-2 Therapy for in Transit Melanoma","volume":"109","author":"Byers","year":"2014","journal-title":"J. Surg. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Kumar, A., Taghi Khani, A., Sanchez Ortiz, A., and Swaminathan, S. (2022). GM-CSF: A Double-Edged Sword in Cancer Immunotherapy. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.901277"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/CJI.0b013e3181a7d60d","article-title":"Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF, Sargramostim) Administered for 3 Years as Adjuvant Therapy of Stages II (T4), III, and IV Melanoma","volume":"32","author":"Spitler","year":"2009","journal-title":"J. Immunother."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/2051-1426-2-11","article-title":"Current Status of Granulocyte\u2013Macrophage Colony-Stimulating Factor in the Immunotherapy of Melanoma","volume":"2","author":"Kaufman","year":"2014","journal-title":"J. ImmunoTherapy Cancer"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Kim, H.J., and Kim, Y.H. (2024). Molecular Frontiers in Melanoma: Pathogenesis, Diagnosis, and Therapeutic Advances. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25052984"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jdcr.2023.10.019","article-title":"Locoregional Melanoma Metastases Resistant to PD-1 Inhibitor Therapy Treated with Intralesional Talimogene Laherparepvec","volume":"43","author":"Wallace","year":"2024","journal-title":"JAAD Case Rep."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Ferrucci, P.F., Pala, L., Conforti, F., and Cocorocchio, E. (2021). Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma. Cancers, 13.","DOI":"10.3390\/cancers13061383"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e006270","DOI":"10.1136\/jitc-2022-006270","article-title":"Talimogene Laherparepvec in Combination with Ipilimumab versus Ipilimumab Alone for Advanced Melanoma: 5-Year Final Analysis of a Multicenter, Randomized, Open-Label, Phase II Trial","volume":"11","author":"Chesney","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1200\/JCO.22.00343","article-title":"Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma","volume":"41","author":"Chesney","year":"2023","journal-title":"JCO"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0748-7983(97)93726-4","article-title":"Carbon Dioxide Laser for Cutaneous Melanoma Metastases: Indications and Limitations","volume":"23","author":"Strobbe","year":"1997","journal-title":"Eur. J. Surg. Oncol. (EJSO)"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"MMT14","DOI":"10.2217\/mmt-2018-0008","article-title":"Application of CO 2 Laser Evaporation in Locally Advanced Melanoma","volume":"6","author":"Vrielink","year":"2019","journal-title":"Melanoma Manag."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s00403-024-03107-9","article-title":"The Palliative Role of Lasers in the Treatment of Melanoma","volume":"316","author":"Algarin","year":"2024","journal-title":"Arch. Dermatol. Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e006629","DOI":"10.1136\/jitc-2022-006629","article-title":"Efficacy and Toxicity of Adjuvant Radiotherapy in Recurrent Melanoma after Adjuvant Immunotherapy","volume":"11","author":"Bhave","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1007\/s11912-024-01557-y","article-title":"Radiation and Melanoma: Where Are We Now?","volume":"26","author":"Bliley","year":"2024","journal-title":"Curr. Oncol. Rep."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1158\/1078-0432.CCR-22-3145","article-title":"Adjuvant Nivolumab versus Ipilimumab in Resected Stage III\/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238","volume":"29","author":"Larkin","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41591-018-0197-1","article-title":"Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable Melanoma","volume":"24","author":"Amaria","year":"2018","journal-title":"Nat. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S1470-2045(21)00065-6","article-title":"Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma (EORTC 1325-MG\/KEYNOTE-054): Distant Metastasis-Free Survival Results from a Double-Blind, Randomised, Controlled, Phase 3 Trial","volume":"22","author":"Eggermont","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant\u2013Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S1470-2045(20)30062-0","article-title":"Adjuvant Dabrafenib plus Trametinib versus Placebo in Patients with Resected, BRAFV600-Mutant, Stage III Melanoma (COMBI-AD): Exploratory Biomarker Analyses from a Randomised, Phase 3 Trial","volume":"21","author":"Dummer","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1470-2045(18)30015-9","article-title":"Neoadjuvant plus Adjuvant Dabrafenib and Trametinib versus Standard of Care in Patients with High-Risk, Surgically Resectable Melanoma: A Single-Centre, Open-Label, Randomised, Phase 2 Trial","volume":"19","author":"Amaria","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S1470-2045(19)30331-6","article-title":"Neoadjuvant Dabrafenib Combined with Trametinib for Resectable, Stage IIIB\u2013C, BRAFV600 Mutation-Positive Melanoma (NeoCombi): A Single-Arm, Open-Label, Single-Centre, Phase 2 Trial","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2021.04.032","article-title":"Clinical Characteristics and Therapy Response in Unresectable Melanoma Patients Stage IIIB-IIID with in-Transit and Satellite Metastases","volume":"152","author":"Zaremba","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.ejso.2022.01.027","article-title":"Isolated Limb Perfusion for Locally Advanced Melanoma in the Immunotherapy Era","volume":"48","author":"Davies","year":"2022","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Rastrelli, M., Russano, F., Cavallin, F., Del Fiore, P., Pacilli, C., Di Prata, C., Rossi, C.R., Vecchiato, A., Dall\u2019Olmo, L., and Mocellin, S. (2024). Isolated Limb Perfusion and Immunotherapy in the Treatment of In-Transit Melanoma Metastases: Is It a Real Synergy?. J. Pers. Med., 14.","DOI":"10.3390\/jpm14050442"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Campana, L.G., Peric, B., Mascherini, M., Spina, R., Kunte, C., Kis, E., Rozsa, P., Quaglino, P., Jones, R.P., and Clover, A.J.P. (2021). Combination of Pembrolizumab with Electrochemotherapy in Cutaneous Metastases from Melanoma: A Comparative Retrospective Study from the InspECT and Slovenian Cancer Registry. Cancers, 13.","DOI":"10.3390\/cancers13174289"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"9559","DOI":"10.1200\/JCO.2019.37.15_suppl.9559","article-title":"Phase 1b Study of PV-10 and Anti-PD-1 in Advanced Cutaneous Melanoma","volume":"37","author":"Agarwala","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_108","first-page":"110","article-title":"Response for Combination of PV-10 Autolytic Immunotherapy and Immune Checkpoint Blockade in Checkpoint-Refractory Patients","volume":"19","author":"Zager","year":"2021","journal-title":"J. Transl. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"9078","DOI":"10.1200\/jco.2014.32.15_suppl.9078","article-title":"Safety and Clinical Activity of Combining Systemic Ipilimumab with Isolated Limb Infusion in Patients with In-Transit Melanoma","volume":"32","author":"Ariyan","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"108265","DOI":"10.1016\/j.ejso.2024.108265","article-title":"The Effect of a Single Dose of Nivolumab Prior to Isolated Limb Perfusion for Patients with In-Transit Melanoma Metastases: An Interim Analysis of a Phase Ib\/II Randomized Double-Blind Placebo-Controlled Trial (NivoILP Trial)","volume":"50","author":"Holmberg","year":"2024","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Johansson, J., Kiffin, R., Andersson, A., Lindn\u00e9r, P., Naredi, P.L., Olofsson Bagge, R., and Martner, A. (2018). Isolated Limb Perfusion with Melphalan Triggers Immune Activation in Melanoma Patients. Front. Oncol., 8.","DOI":"10.3389\/fonc.2018.00570"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"9028","DOI":"10.1200\/jco.2014.32.15_suppl.9028","article-title":"Assessment of Immune and Clinical Efficacy after Intralesional PV-10 in Injected and Uninjected Metastatic Melanoma Lesions","volume":"32","author":"Sarnaik","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Wachter, E.A., Blair, S.O., Singer, J.M., and Dees, H.C. (2013). CombinaTon of PV\u201310 Immuno\u2013chemoablaTon and Systemic anT\u2013CTLA\u20134 AnTbody Therapy in Murine Models of Melanoma, AMER Assoc Cancer Research 615 Chestnut St, 17th Floor.","DOI":"10.1158\/1538-7445.AM2013-4755"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1245\/s10434-014-4169-5","article-title":"Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma","volume":"22","author":"Thompson","year":"2015","journal-title":"Ann. Surg. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/17\/3065\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:47:44Z","timestamp":1760111264000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/17\/3065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,3]]},"references-count":114,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["cancers16173065"],"URL":"https:\/\/doi.org\/10.3390\/cancers16173065","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,3]]}}}